MetaVia Inc. Announces 1-for-11 Reverse Stock Split

Core Viewpoint - MetaVia Inc. announced a 1-for-11 reverse stock split of its common stock, effective December 4, 2025, to comply with Nasdaq's continued listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 11 shares of common stock into one share, maintaining the par value of $0.001 per share [2][3]. - Following the split, the number of outstanding shares will decrease from approximately 25.4 million to about 2.3 million, while the authorized shares will remain at 100 million [4]. Group 2: Impact on Stock Options and Warrants - The reverse stock split will proportionately reduce the number of shares issuable upon conversion of restricted stock units, stock options, and warrants, while increasing their conversion and exercise prices accordingly [3]. Group 3: Company Overview - MetaVia Inc. is focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity treatment and vanoglipel (DA-1241) for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [6]. - DA-1726 is a dual agonist that has shown best-in-class potential for weight loss and glucose control in Phase 1 trials [6]. - Vanoglipel has demonstrated positive effects on liver inflammation and glucose metabolism in pre-clinical studies and Phase 2a clinical trials [6].